In addition, we found that PIs inhibit ERα expression and disrupt signaling pathways that mediate resistance to commonly used treatment regimens in ER+/HER2− breast cancer [34], and that PIs inhibit HER2 through multiple mechanisms [34,35]. This evidence concerns the gene ERBB2 and breast cancer.